Economic Burden and Health Complications of Hypertrophic Cardiomyopathy: Is the Field Ready for Value-Based Care?
Abstract
Despite advances in diagnosis and treatment, hypertrophic cardiomyopathy (HCM) continues to impose a substantial and growing burden on patients and health care systems. Historically recognized primarily for its association with sudden cardiac death in young individuals, the clinical paradigm of HCM has evolved. It is now understood as a complex, chronic disorder requiring lifelong management of progressive symptoms and recurrent hospitalizations.1 Definitive treatment strategies have largely focused on symptom relief through pharmacotherapy and septal reduction therapy (SRT) for obstructive disease.
Fields of Study & Subjects
Cardiomyopathy and Myosin Studies
Health Systems
Economic Evaluations
Quality of Life
Healthcare Policy and Management
Publication details
- Journal / source
- Journal of Cardiac Failure - Intersections
- Volume
- 2
- Issue
- 2
- Pages
- 109–111
- Publication date
- 6 February 2026
- Language
- EN